Ignite Creation Date:
2024-05-05 @ 5:28 PM
Last Modification Date:
2024-10-26 @ 9:32 AM
Study NCT ID:
NCT00460642
Status:
COMPLETED
Last Update Posted:
2010-05-26
First Post:
2007-04-12
Brief Title:
GnRH Antagonist to Prepare Recipients for Embryo Transfer
Sponsor:
Institute for Human Reproduction IHR
Organization:
Institute for Human Reproduction IHR
Study Overview
Official Title:
Use of GnRH Antagonist Cetrotide Protocol Instead of Agonist to Prepare Recipients for Embryo Transfer
Status:
COMPLETED
Status Verified Date:
2010-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
26 of all ART cycles performed in the USA in 2003 CDC data are frozen embryo transfers FET and transfer of embryos resulting from egg donation ED to recipients The typical protocol used to prepare a recipient for ET involves GnRH agonist Lupron Tap Pharmaceuticals to down regulate the patient A GnRH antagonist such as Cetrotide EMD Serono is comparable to GnRH agonist and FDA approved to prevent spontaneous ovulation with ART treatment and its usage decreases significantly the number of injections that the patient receives with treatment The working hypothesis for this study is that the GnRH antagonist Cetrotide can be used instead of an agonist to achieve effective down regulation in FET and ED cycles Presumably patients will prefer Cetrotide over Lupron because of the markedly fewer injections required
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None